GTC Enters $15M Debt Financing With French Partner
Framingham-based GTC Biotherapeutics will secure $15 million in convertible debt with liens on its intellectual property and all its other assets in order to raise $10 million.
The company's shareholders approved issuing $15 million in convertible bonds to Paris-based LFB Biotechnologies. The bonds will mature in 2012, will bear an annual interest rate of 8 percent and can be converted to GTC common stock at $0.31 per share at LFB's discretion.
GTC and LFB have been partners in the development of certain plasma proteins since 2006.
Under the agreement, GTC is required to put $4 million of the proceeds in a cash account to secure its existing debt to GE Capital. LFB also has the right to require GTC to redeem stock warrants that are part of the financing agreement for $1.5 million if the debt is repaid in full.
GTC said it would use the approximately $10 million raised in the arrangement for "corporate purposes across all programs."
GTC is developing a protein-based treatment for the prevention of blood clots in surgery patients. The protein used in the treatment is produced in the milk of genetically modified goats.
WBJ Web Partners
Most Recent
Most Recent
0 Comments